News for Purple Biotech Ltd. (PPBT)

Purple Biotech (PPBT) recently shared a letter from CEO Gil Efron, outlining significant achievements and future objectives in the first half of 2025. The compa

Purple Biotech's (PPBT) CAPTN-3 platform shows promising preclinical results with tri-specific antibodies. IM1240, the lead product, ind

Purple Biotech (PPBT) initiates Phase 2 study of NT219 in Head and Neck Cancer patients. NT219 targets resistance pathways, combining with pembrolizumab

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in combination with either pembrolizumab or c

Purple Biotech (PPBT) to present a poster on its CAPTN-3 tri-specific antibody platform at EACR 2025. Presentation scheduled for June 17, 2025, during t

REHOVOT, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company devel

Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Secon

Purple Biotech (PPBT) reported a significant reduction in R&D expenses, resulting in an operating loss decrease of 68.9% YoY for Q1 2025.Final data from the CM

U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational exc

Purple Biotech (PPBT) appoints Shai Lankry as the new Chief Financial Officer. Lankry brings over 20 years of financial leadership in biotech and health

Statistically significant efficacy in biomarker subgroup analyses was observed: 78% reduction in risk of death and 81% reduction in risk of progression or

Activated b-catenin or loss of its negative regulator adenomatous polyposis coli (APC) is a potential biomarker for NT219 in the treatment of colorectal cancerN

**media[607529]**

\n NT219, a drug developed by Purple Biotech (PPBT), shows promise in suppressing brain metastasis in colorectal cancer. The study identifies IRS2 as a cru

**media[596629]**

**media[582605]**

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company dev

Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkers CM24 is well posi

NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March 05, 2025 (